Open Orphan PLC
LSE:ORPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Trina Solar Co Ltd
SSE:688599
|
CN |
|
Santana Minerals Ltd
ASX:SMI
|
AU |
|
ICICI Bank Ltd
NSE:ICICIBANK
|
IN |
|
H
|
Hangzhou Heshun Technology Co Ltd
SZSE:301237
|
CN |
|
Sony Group Corp
NYSE:SONY
|
JP |
|
V
|
Vikas Lifecare Ltd
BSE:542655
|
IN |
|
C
|
Costamare Inc
NYSE:CMRE
|
MC |
Open Orphan PLC
Total Current Assets
Open Orphan PLC
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Total Current Assets
£42.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Total Current Assets
£420m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Total Current Assets
£29.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Total Current Assets
£1.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-12%
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Total Current Assets
£1.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Total Current Assets
£42.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
32%
|
|
Open Orphan PLC
Glance View
Open Orphan Plc provides pharmaceutical development services. The firm is engaged in the testing of vaccines and antivirals using human clinical trials. The firm has a presence in the United Kingdom, Ireland, France and Netherlands. The Company, through its subsidiary hVIVO Limited, is also engaged in the data platform business. hVIVO Limited has built up databases of infectious disease progression data and the Company is populating its Open Orphan Health Data platform with hVIVO data. The firm also operates through its subsidiary Venn Life Sciences, which is an integrated drug development partner. Venn Life Sciences offers a combination of drug development consultancy, clinical trial design and execution to create, plan and execute drug development programs for its customers.
See Also
What is Open Orphan PLC's Total Current Assets?
Total Current Assets
42.2m
GBP
Based on the financial report for Dec 31, 2022, Open Orphan PLC's Total Current Assets amounts to 42.2m GBP.
What is Open Orphan PLC's Total Current Assets growth rate?
Total Current Assets CAGR 1Y
67%
Over the last year, the Total Current Assets growth was 67%.
